Adeka (4401) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
10 Mar, 2026Executive summary
Q1 FY2025 net sales rose 3.5% year-over-year to JPY 101.6 billion, with operating profit up 26.6% to JPY 10.99 billion and profit attributable to owners of parent up 6.2% to JPY 7.25 billion.
Net profit per share increased to JPY 71.22, up JPY 4.4 year-over-year.
Growth was driven by strong Life Science segment performance, offsetting declines in Chemicals and Food Products.
Comprehensive income declined 19.0% year-over-year to JPY 10.23 billion.
The global economy showed solid growth, but uncertainties remain due to U.S. tariff policy.
Financial highlights
Operating profit increased by JPY 2.3 billion year-over-year, mainly due to higher sales volume and improved net pricing, despite negative impacts from exchange rates and fixed costs.
Ordinary profit rose 13.7% year-over-year to JPY 11.06 billion.
Gross profit increased to JPY 28.95 billion from JPY 26.38 billion year-over-year.
Overseas sales ratio stood at 54.6% at Q1 end.
Q1 progress rate: 23% for net sales, 25% for operating profit toward full-year targets.
Outlook and guidance
FY2025 forecasts unchanged: JPY 441 billion net sales (+8.3% YoY), JPY 43 billion operating profit (+4.9% YoY), JPY 26.4 billion profit attributable to owners, JPY 259.5 net profit per share.
Dividend forecast raised to JPY 104 per share for the fiscal year ending March 31, 2026.
Segment forecasts adjusted: downward for Polymer Additives and Semiconductor Materials, upward for Life Science due to strong agrochemical sales.
Expecting significant recovery in H2 for semiconductor materials, but not enough to offset H1 decline.
FX sensitivity: a JPY 1 appreciation against the USD impacts operating profit by JPY 0.09 billion.
Latest events from Adeka
- Life Science strength drove profit growth, offsetting Chemicals and Food Products weakness.4401
Q2 202610 Mar 2026 - Profits and sales grew, led by Chemicals and Food Products, with raised outlook and Life Science loss.4401
Q1 202510 Mar 2026 - Strategic investments and innovation in semiconductor materials target rapid global growth.4401
Investor presentation10 Mar 2026 - 3Q FY2024 saw higher sales and profits, driven by Chemicals and global expansion.4401
Q3 202510 Mar 2026 - Strong 1H FY2024 results and Chemicals growth led to higher guidance and dividend forecasts.4401
Q2 202510 Mar 2026 - Record sales and profit growth driven by Chemicals, with continued expansion and higher dividends forecast.4401
Q4 202510 Mar 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 202610 Mar 2026